# pathway_0197

[All questions](../README.md) · [Summary](../SUMMARY.md) · [Method](../METHOD.md) · [Exact reviewer input](../inputs/pathway_0197.txt)

**Task:** `pathway`  
**Expected answer:** **C** — Antifungal biosynthesis. .

| Reviewer | Expected-answer support | Reasoning versus lookup |
|---|---|---|
| GPT-6 Luna | supported | lookup-dependent |
| Qwen3.8-Flash-Next-NVFP4 | supported | lookup-dependent |

The reviewers assess the question and its expected answer. Their agreement is not expert confirmation. An unusable review is an output failure, not a finding that the question is wrong.

## Complete original question

```text
[Protein Sequence]
MKAIISVSPGRAALVHDRPLPSLRNGYLLVRTKAVALNPTDWKHIEITERPGILFGCDYAGVVEKIGPGISSRFQVGDRVAGFVHGGNSQEPQDGAFAEYILAKADIQILIPEHMSFEEAATLGVGVTSVGQGLYQALQLPFPGTQGEDPKTPTEEQQPLLIYGGSTASGVLGIQFAKLSGFAPLAVCSPDHFDLVETLGAVAQFDYADGEEAVQEIQDYVDRMSKPLRLAWDTVSIPSSAQFCGDALSALDECHYASLLPIKCQRSDVTSTTTMAYTVFGEDWGMGATRFPAVATDAEFGRRWWALVQELLDQGRIQTHRIIIGENGLDGVLAGLERLRDSQVRGAKLVYRV

[Multiple Choices]
A. O-acetyl-L-homoserine from L-homoserine: step 1/1. .
B. Protein biosynthesis
C. Antifungal biosynthesis. .
D. Secondary metabolite biosynthesis. .
```

<details>
<summary>Complete original system instructions</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## Reviewer assessments

## GPT-6 Luna

**Saved status:** `valid_review`.

### Expected-answer support: supported

> The sequence-matched UniProt annotation assigns the protein to antifungal biosynthesis and cites experimental evidence (ECO:0000269) and a publication. This supports the key, though the underlying study was not independently evaluated here.

Citations as saved: [C5](#evidence-c5), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence is compatible with an enzyme involved in specialized-metabolite biosynthesis, which makes the broad secondary-metabolite option plausible. But an enzyme's general catalytic role does not establish that its product is antifungal rather than another specialized metabolite.


**Missing item-specific fact**

> The protein's assignment to the biosynthetic cluster for an antifungal product, or equivalent target-specific pathway evidence.


**Reason**

> The offered choices include both a broad secondary-metabolite category and the narrower antifungal-biosynthesis category. The sequence alone does not provide a credible basis to make that product-specific distinction; it requires information about this protein's pathway or cluster.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "C",
  "D"
]
```

> Antifungal biosynthesis is a form of secondary-metabolite biosynthesis, so both choices can describe the protein at different levels of specificity. The question does not specify that the most specific applicable pathway must be selected.


### Important caveats

- The supporting pathway annotation cites experimental evidence, but the primary study was not independently checked.
- Reviewer-only source identity and annotations were not part of the original model input and do not establish sequence-only answerability.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence is compatible with an enzyme involved in specialized-metabolite biosynthesis, which makes the broad secondary-metabolite option plausible. But an enzyme's general catalytic role does not establish that its product is antifungal rather than another specialized metabolite.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein's assignment to the biosynthetic cluster for an antifungal product, or equivalent target-specific pathway evidence.",
    "reason": "The offered choices include both a broad secondary-metabolite category and the narrower antifungal-biosynthesis category. The sequence alone does not provide a credible basis to make that product-specific distinction; it requires information about this protein's pathway or cluster."
  },
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "evidence_ids": [
      "C5",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The sequence-matched UniProt annotation assigns the protein to antifungal biosynthesis and cites experimental evidence (ECO:0000269) and a publication. This supports the key, though the underlying study was not independently evaluated here."
  },
  "important_caveats": [
    "The supporting pathway annotation cites experimental evidence, but the primary study was not independently checked.",
    "Reviewer-only source identity and annotations were not part of the original model input and do not establish sequence-only answerability."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "C",
      "D"
    ],
    "reason": "Antifungal biosynthesis is a form of secondary-metabolite biosynthesis, so both choices can describe the protein at different levels of specificity. The question does not specify that the most specific applicable pathway must be selected."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The sequence-matched UniProt annotation assigns the protein to antifungal biosynthesis and cites experimental evidence (ECO:0000269) and a publication. This supports the key, though the underlying study was not independently evaluated here.",
    "evidence_ids": ["C5", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence is compatible with an enzyme involved in specialized-metabolite biosynthesis, which makes the broad secondary-metabolite option plausible. But an enzyme's general catalytic role does not establish that its product is antifungal rather than another specialized metabolite.",
    "missing_item_specific_fact": "The protein's assignment to the biosynthetic cluster for an antifungal product, or equivalent target-specific pathway evidence.",
    "reason": "The offered choices include both a broad secondary-metabolite category and the narrower antifungal-biosynthesis category. The sequence alone does not provide a credible basis to make that product-specific distinction; it requires information about this protein's pathway or cluster."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["C", "D"],
    "reason": "Antifungal biosynthesis is a form of secondary-metabolite biosynthesis, so both choices can describe the protein at different levels of specificity. The question does not specify that the most specific applicable pathway must be selected."
  },
  "important_caveats": [
    "The supporting pathway annotation cites experimental evidence, but the primary study was not independently checked.",
    "Reviewer-only source identity and annotations were not part of the original model input and do not establish sequence-only answerability."
  ]
}
```

</details>

## Qwen3.8-Flash-Next-NVFP4

**Saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry A0A0L1JEX1 (RSTN7_ASPN3) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (experimental) from PubMed:33857369. The protein is 'Trans-enoyl reductase rstn7,' a component of the restricticin biosynthetic gene cluster. Restricticin is a natural product CYP51 inhibitor, and CYP51 inhibition confers antifungal activity. The annotation is directly supported by experimental characterization in the cited JACS 2021 paper.

Citations as saved: [C5](#evidence-c5), [C6](#evidence-c6), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence contains multiple glycine-rich Rossmann-fold-like motifs (GCDYAGVVEKIGPG, GGSTASGVLGIQFAKLSGF, ENGLDGVLAGLERLR) characteristic of an oxidoreductase, likely a trans-enoyl reductase component of a fungal polyketide synthase. This eliminates A (homoserine O-acetyltransferase, a transferase) and B (ribosomal/translation machinery). However, distinguishing C ('Antifungal biosynthesis') from D ('Secondary metabolite biosynthesis') requires knowing that this specific trans-enoyl reductase belongs to the restricticin cluster AND that restricticin's biological activity is antifungal (CYP51 inhibition). Trans-enoyl reductases are generic PKS components found in many fungal secondary metabolite pathways (aflatoxin, lovastatin, gliotoxin, etc.), and their sequences do not encode information about the biological activity of the final polyketide product. No sequence feature or family-level inference distinguishes an antifungal-targeting PKS from one producing an antibacterial or other bioactive secondary metabolite.


**Missing item-specific fact**

> The specific identity of the biosynthetic gene cluster (restricticin) and the experimentally determined antifungal (CYP51-inhibitory) activity of the end product, which together justify the specific 'Antifungal biosynthesis' pathway annotation over the general 'Secondary metabolite biosynthesis' category.


**Reason**

> From the sequence alone, a model can identify an oxidoreductase likely involved in fungal secondary metabolism (polyketide biosynthesis), but cannot determine whether the end product is specifically antifungal versus any other class of secondary metabolite. The C vs D distinction depends on knowing the biological activity of restricticin, which is a fact specific to this protein's role in this particular biosynthetic cluster.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "C",
  "D"
]
```

> Restricticin is both a secondary metabolite and an antifungal compound. 'Secondary metabolite biosynthesis' (D) is the general biochemical category, while 'Antifungal biosynthesis' (C) is the specific functional annotation in UniProt. Without the taxonomy hierarchy being explicit in the question, a model could argue D is the broader correct category encompassing C, or that C is the more specific pathway annotation. The distinction requires knowing the benchmark's pathway taxonomy treats these as mutually exclusive categories with C being the specific assigned pathway.


### Important caveats

- The UniProt 'Antifungal biosynthesis' pathway annotation (ECO:0000269) is based on experimental characterization of the restricticin cluster's CYP51-inhibitory activity, not on sequence analysis of this individual enzyme.
- The sequence identifies the protein as a trans-enoyl reductase (oxidoreductase), which is consistent with both C and D but does not uniquely specify either.
- The reviewer-only evidence confirms sequence match to A0A0L1JEX1 (353 aa, SHA256 match), but this accession and organism identity were not available to the evaluated model.
- The historical entry (version 28, released 2026-01-28) already contained the 'Antifungal biosynthesis' pathway annotation, so the key was available in the database at the approximate benchmark construction time.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence contains multiple glycine-rich Rossmann-fold-like motifs (GCDYAGVVEKIGPG, GGSTASGVLGIQFAKLSGF, ENGLDGVLAGLERLR) characteristic of an oxidoreductase, likely a trans-enoyl reductase component of a fungal polyketide synthase. This eliminates A (homoserine O-acetyltransferase, a transferase) and B (ribosomal/translation machinery). However, distinguishing C ('Antifungal biosynthesis') from D ('Secondary metabolite biosynthesis') requires knowing that this specific trans-enoyl reductase belongs to the restricticin cluster AND that restricticin's biological activity is antifungal (CYP51 inhibition). Trans-enoyl reductases are generic PKS components found in many fungal secondary metabolite pathways (aflatoxin, lovastatin, gliotoxin, etc.), and their sequences do not encode information about the biological activity of the final polyketide product. No sequence feature or family-level inference distinguishes an antifungal-targeting PKS from one producing an antibacterial or other bioactive secondary metabolite.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The specific identity of the biosynthetic gene cluster (restricticin) and the experimentally determined antifungal (CYP51-inhibitory) activity of the end product, which together justify the specific 'Antifungal biosynthesis' pathway annotation over the general 'Secondary metabolite biosynthesis' category.",
    "reason": "From the sequence alone, a model can identify an oxidoreductase likely involved in fungal secondary metabolism (polyketide biosynthesis), but cannot determine whether the end product is specifically antifungal versus any other class of secondary metabolite. The C vs D distinction depends on knowing the biological activity of restricticin, which is a fact specific to this protein's role in this particular biosynthetic cluster."
  },
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "evidence_ids": [
      "C5",
      "C6",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEX1 (RSTN7_ASPN3) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (experimental) from PubMed:33857369. The protein is 'Trans-enoyl reductase rstn7,' a component of the restricticin biosynthetic gene cluster. Restricticin is a natural product CYP51 inhibitor, and CYP51 inhibition confers antifungal activity. The annotation is directly supported by experimental characterization in the cited JACS 2021 paper."
  },
  "important_caveats": [
    "The UniProt 'Antifungal biosynthesis' pathway annotation (ECO:0000269) is based on experimental characterization of the restricticin cluster's CYP51-inhibitory activity, not on sequence analysis of this individual enzyme.",
    "The sequence identifies the protein as a trans-enoyl reductase (oxidoreductase), which is consistent with both C and D but does not uniquely specify either.",
    "The reviewer-only evidence confirms sequence match to A0A0L1JEX1 (353 aa, SHA256 match), but this accession and organism identity were not available to the evaluated model.",
    "The historical entry (version 28, released 2026-01-28) already contained the 'Antifungal biosynthesis' pathway annotation, so the key was available in the database at the approximate benchmark construction time."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "C",
      "D"
    ],
    "reason": "Restricticin is both a secondary metabolite and an antifungal compound. 'Secondary metabolite biosynthesis' (D) is the general biochemical category, while 'Antifungal biosynthesis' (C) is the specific functional annotation in UniProt. Without the taxonomy hierarchy being explicit in the question, a model could argue D is the broader correct category encompassing C, or that C is the more specific pathway annotation. The distinction requires knowing the benchmark's pathway taxonomy treats these as mutually exclusive categories with C being the specific assigned pathway."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEX1 (RSTN7_ASPN3) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (experimental) from PubMed:33857369. The protein is 'Trans-enoyl reductase rstn7,' a component of the restricticin biosynthetic gene cluster. Restricticin is a natural product CYP51 inhibitor, and CYP51 inhibition confers antifungal activity. The annotation is directly supported by experimental characterization in the cited JACS 2021 paper.",
    "evidence_ids": ["C5", "C6", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence contains multiple glycine-rich Rossmann-fold-like motifs (GCDYAGVVEKIGPG, GGSTASGVLGIQFAKLSGF, ENGLDGVLAGLERLR) characteristic of an oxidoreductase, likely a trans-enoyl reductase component of a fungal polyketide synthase. This eliminates A (homoserine O-acetyltransferase, a transferase) and B (ribosomal/translation machinery). However, distinguishing C ('Antifungal biosynthesis') from D ('Secondary metabolite biosynthesis') requires knowing that this specific trans-enoyl reductase belongs to the restricticin cluster AND that restricticin's biological activity is antifungal (CYP51 inhibition). Trans-enoyl reductases are generic PKS components found in many fungal secondary metabolite pathways (aflatoxin, lovastatin, gliotoxin, etc.), and their sequences do not encode information about the biological activity of the final polyketide product. No sequence feature or family-level inference distinguishes an antifungal-targeting PKS from one producing an antibacterial or other bioactive secondary metabolite.",
    "missing_item_specific_fact": "The specific identity of the biosynthetic gene cluster (restricticin) and the experimentally determined antifungal (CYP51-inhibitory) activity of the end product, which together justify the specific 'Antifungal biosynthesis' pathway annotation over the general 'Secondary metabolite biosynthesis' category.",
    "reason": "From the sequence alone, a model can identify an oxidoreductase likely involved in fungal secondary metabolism (polyketide biosynthesis), but cannot determine whether the end product is specifically antifungal versus any other class of secondary metabolite. The C vs D distinction depends on knowing the biological activity of restricticin, which is a fact specific to this protein's role in this particular biosynthetic cluster."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["C", "D"],
    "reason": "Restricticin is both a secondary metabolite and an antifungal compound. 'Secondary metabolite biosynthesis' (D) is the general biochemical category, while 'Antifungal biosynthesis' (C) is the specific functional annotation in UniProt. Without the taxonomy hierarchy being explicit in the question, a model could argue D is the broader correct category encompassing C, or that C is the more specific pathway annotation. The distinction requires knowing the benchmark's pathway taxonomy treats these as mutually exclusive categories with C being the specific assigned pathway."
  },
  "important_caveats": [
    "The UniProt 'Antifungal biosynthesis' pathway annotation (ECO:0000269) is based on experimental characterization of the restricticin cluster's CYP51-inhibitory activity, not on sequence analysis of this individual enzyme.",
    "The sequence identifies the protein as a trans-enoyl reductase (oxidoreductase), which is consistent with both C and D but does not uniquely specify either.",
    "The reviewer-only evidence confirms sequence match to A0A0L1JEX1 (353 aa, SHA256 match), but this accession and organism identity were not available to the evaluated model.",
    "The historical entry (version 28, released 2026-01-28) already contained the 'Antifungal biosynthesis' pathway annotation, so the key was available in the database at the approximate benchmark construction time."
  ]
}
```

</details>

## Complete reviewer-only evidence and qualifications

These source excerpts were available to the reviewers. They were not included in the original benchmark-solving input.

**Source applicability:**

```json
{
  "actual_author_source_snapshot": "unknown",
  "benchmark_sequence_length": 353,
  "benchmark_sequence_sha256": "39f6a97cab7f2cacfcd71868b53ec0e747754ce4dcb5969ed28596b1d58ba3ca",
  "current_entry_audit": {
    "entryVersion": 30,
    "firstPublicDate": "2025-02-05",
    "lastAnnotationUpdateDate": "2026-09-02",
    "lastSequenceUpdateDate": "2015-11-11",
    "sequenceVersion": 1
  },
  "current_record_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "current_sequence_comparison": "matched",
  "current_source_sequence_length": 353,
  "current_source_sequence_sha256": "39f6a97cab7f2cacfcd71868b53ec0e747754ce4dcb5969ed28596b1d58ba3ca",
  "current_status": "retrieved",
  "current_uniprot_release": "2026_03",
  "historical_cutoff_date": "2026-05-07",
  "historical_sequence_comparison": "matched",
  "historical_sequence_versions_checked": [
    {
      "entry_version": 28,
      "exact_sequence_comparison": "matched",
      "sequence_version": 1
    }
  ],
  "historical_status": "retrieved",
  "identity_origin": "reviewer-only accession inferred mechanically from original dataset image-path metadata; this accession/metadata was absent from evaluated model input",
  "latest_at_cutoff_sequence_comparison": "matched",
  "numbering": "Canonical entry coordinates; construct or isoform numbering is not assumed.",
  "requested_accession": "A0A0L1JEX1",
  "selected_historical_entry_version": 28,
  "selected_historical_record_sha256": "b0c5088300010a6f92ba849941ad2568759c78d66be84ee67a93fca4e39f4e91",
  "selected_historical_source_sequence_length": 353,
  "selected_historical_source_sequence_sha256": "39f6a97cab7f2cacfcd71868b53ec0e747754ce4dcb5969ed28596b1d58ba3ca",
  "selected_historical_version": {
    "accession": "A0A0L1JEX1",
    "database": "Swiss-Prot",
    "entryVersion": 28,
    "firstRelease": "2026_01/2026_01",
    "firstReleaseDate": "28-Jan-2026",
    "lastRelease": "2026_01/2026_01",
    "lastReleaseDate": "28-Jan-2026",
    "name": "RSTN7_ASPN3",
    "sequenceVersion": 1
  }
}
```

**Qualifications:**

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C1",
  "excerpt": "\"A0A0L1JEX1\"",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "json_pointer": "/primaryAccession",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "sequence_comparison": "matched",
  "source": "UniProtKB current entry",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json"
}
```

### Evidence C2

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C2",
  "excerpt": "{\"entryVersion\":30,\"firstPublicDate\":\"2025-02-05\",\"lastAnnotationUpdateDate\":\"2026-09-02\",\"lastSequenceUpdateDate\":\"2015-11-11\",\"sequenceVersion\":1}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "json_pointer": "/entryAudit",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "sequence_comparison": "matched",
  "source": "UniProtKB current entry",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json"
}
```

### Evidence C3

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C3",
  "excerpt": "{\"lineage\":[\"Eukaryota\",\"Fungi\",\"Dikarya\",\"Ascomycota\",\"Pezizomycotina\",\"Eurotiomycetes\",\"Eurotiomycetidae\",\"Eurotiales\",\"Aspergillaceae\",\"Aspergillus\",\"Circumdati\"],\"scientificName\":\"Aspergillus nomiae NRRL (strain ATCC 15546 / NRRL 13137 / CBS 260.88 / M93)\",\"taxonId\":1509407}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "json_pointer": "/organism",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "sequence_comparison": "matched",
  "source": "UniProtKB current entry",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json"
}
```

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C4",
  "excerpt": "{\"alternativeNames\":[{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"Restricticin biosynthesis cluster protein 7\"}}],\"recommendedName\":{\"ecNumbers\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000305\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"1.-.-.-\"}],\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"Trans-enoyl reductase rstn7\"}}}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "json_pointer": "/proteinDescription",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "sequence_comparison": "matched",
  "source": "UniProtKB current entry",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json"
}
```

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C5",
  "excerpt": "{\"commentType\":\"PATHWAY\",\"texts\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000269\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"Antifungal biosynthesis\"}]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "json_pointer": "/comments/1",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "sequence_comparison": "matched",
  "source": "UniProtKB current entry",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json"
}
```

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C6",
  "excerpt": "{\"citation\":{\"authors\":[\"Liu N.\",\"Abramyan E.D.\",\"Cheng W.\",\"Perlatti B.\",\"Harvey C.J.B.\",\"Bills G.F.\",\"Tang Y.\"],\"citationCrossReferences\":[{\"database\":\"PubMed\",\"id\":\"33857369\"},{\"database\":\"DOI\",\"id\":\"10.1021/jacs.1c01516\"}],\"citationType\":\"journal article\",\"firstPage\":\"6043\",\"id\":\"33857369\",\"journal\":\"J. Am. Chem. Soc.\",\"lastPage\":\"6047\",\"publicationDate\":\"2021\",\"title\":\"Targeted genome mining reveals the biosynthetic gene clusters of natural product CYP51 inhibitors.\",\"volume\":\"143\"},\"referenceNumber\":2,\"referencePositions\":[\"FUNCTION\",\"PATHWAY\"]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "json_pointer": "/references/1",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "sequence_comparison": "matched",
  "source": "UniProtKB current entry",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json"
}
```

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28)

```json
{
  "entry_version": 28,
  "evidence_id": "H1",
  "excerpt": "ID   RSTN7_ASPN3             Reviewed;         353 AA.\nAC   A0A0L1JEX1;\nDT   05-FEB-2025, integrated into UniProtKB/Swiss-Prot.\nDT   11-NOV-2015, sequence version 1.\nDT   28-JAN-2026, entry version 28.\nDE   RecName: Full=Trans-enoyl reductase rstn7 {ECO:0000303|PubMed:33857369};\nDE            EC=1.-.-.- {ECO:0000305|PubMed:33857369};\nDE   AltName: Full=Restricticin biosynthesis cluster protein 7 {ECO:0000303|PubMed:33857369};\nGN   Name=rstn7 {ECO:0000303|PubMed:33857369}; ORFNames=ANOM_001446;\nOS   Aspergillus nomiae NRRL (strain ATCC 15546 / NRRL 13137 / CBS 260.88 /\nOS   M93).\nOC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Eurotiomycetes;\nOC   Eurotiomycetidae; Eurotiales; Aspergillaceae; Aspergillus;\nOC   Aspergillus subgen. Circumdati.\nOX   NCBI_TaxID=1509407;\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "retrieved_utc": "2026-11-02T04:24:15.236581+00:00",
  "sequence_comparison": "matched",
  "sequence_version": 1,
  "source": "UniSave archived UniProt entry",
  "source_locator": "lines 1-15",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "source_sha256": "b0c5088300010a6f92ba849941ad2568759c78d66be84ee67a93fca4e39f4e91",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28"
}
```

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28)

```json
{
  "entry_version": 28,
  "evidence_id": "H2",
  "excerpt": "RN   [2]\nRP   FUNCTION, AND PATHWAY.\nRX   PubMed=33857369; DOI=10.1021/jacs.1c01516;\nRA   Liu N., Abramyan E.D., Cheng W., Perlatti B., Harvey C.J.B., Bills G.F.,\nRA   Tang Y.;\nRT   \"Targeted genome mining reveals the biosynthetic gene clusters of natural\nRT   product CYP51 inhibitors.\";\nRL   J. Am. Chem. Soc. 143:6043-6047(2021).\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "retrieved_utc": "2026-11-02T04:24:15.236581+00:00",
  "sequence_comparison": "matched",
  "sequence_version": 1,
  "source": "UniSave archived UniProt entry",
  "source_locator": "lines 24-31",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "source_sha256": "b0c5088300010a6f92ba849941ad2568759c78d66be84ee67a93fca4e39f4e91",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28"
}
```

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28)

```json
{
  "entry_version": 28,
  "evidence_id": "H3",
  "excerpt": "CC   -!- PATHWAY: Antifungal biosynthesis. {ECO:0000269|PubMed:33857369}.\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "retrieved_utc": "2026-11-02T04:24:15.236581+00:00",
  "sequence_comparison": "matched",
  "sequence_version": 1,
  "source": "UniSave archived UniProt entry",
  "source_locator": "lines 47-47",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "source_sha256": "b0c5088300010a6f92ba849941ad2568759c78d66be84ee67a93fca4e39f4e91",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28"
}
```

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 197. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). [Source credits](../THIRD_PARTY_NOTICES.md).
